Journal of Clinical Medicine (Jul 2020)

Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms

  • Edoardo Benedetti,
  • Rita Tavarozzi,
  • Riccardo Morganti,
  • Benedetto Bruno,
  • Emilia Bramanti,
  • Claudia Baratè,
  • Serena Balducci,
  • Lorenzo Iovino,
  • Federica Ricci,
  • Vittorio Ricchiuto,
  • Gabriele Buda,
  • Sara Galimberti

DOI
https://doi.org/10.3390/jcm9072149
Journal volume & issue
Vol. 9, no. 7
p. 2149

Abstract

Read online

To define the role of spleen stiffness (SS) and liver stiffness (LS) in myelofibrosis and other Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs), we studied, by ultrasonography (US) and elastography (ES), 70 consecutive patients with myelofibrosis (MF) (no.43), essential thrombocythemia (ET) (no.10), and polycythemia vera (PV) (no.17). Overall, the median SS was not different between patients with MF and PV (p = 0.9); however, both MF and PV groups had significantly higher SS than the ET group (p = 0.011 and p = 0.035, respectively) and healthy controls (p p = 0.002, respectively). In patients with MF, SS values above 40 kPa were significantly associated with worse progression-free survival (PFS) (p = 0.012; HR = 3.2). SS also correlated with the extension of bone marrow fibrosis (BMF) (p p p = 0.038; HR = 2.61). LS significantly differed between the patient cohort with MF and healthy controls (p = 0.001), but not between the patient cohorts with ET and PV and healthy controls (p = 0.999 and p = 0.101, respectively). We can conclude that organ stiffness adds valuable information to the clinical work-up of MPNs and could be employed to define patients at a higher risk of progression.

Keywords